Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

By afschroeder • October 25, 2025

Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov;26(7):e503-e513.e11. doi: 10.1016/j.cllc.2025.05.016. Epub 2025 Jun 6. PMID: 40582920.

Tags: ALK inhibitors, Cedars Sinai DoM, circulating tumor DNA, G1202R, Hematology/Oncology, Publications, Resistance mutations, Tumor biopsy

Temporal trends in the clinical utilization of cardiac imaging tests: 2008-2024

Rozanski A, Gransar H, Miller R, Slomka P, Han D, Hayes S, Friedman J, Berman D. Temporal trends in the clinical utilization of cardiac imaging[...]

Improved Assessment of Coronary Artery Disease in Obese Subjects with Flurpiridaz-18F PET Myocardial Perfusion Imaging: A Prespecified Subgroup Analysis of the AURORA Phase 3 Study

Patel KK, Maddahi J, Agostini D, Bax JJ, Beanlands RSB, Berman D, Dorbala S, Heller GV, Knuuti JM, Pelletier-Galarneau M, Tamaki N, Thompson D, Somer[...]

30-Day Outcomes of a Single-Stage Transfemoral Mitral Valve Replacement System in Severe Mitral Valve Disease

Yadav PK, Vahl TP, Thourani VH, Latib A, Chehab BM, Rinaldi M, Makkar R, Rogers JH, Rodés-Cabau J, Singh G, Gössl M, Sorajja P, Reardon[...]